Limits...
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.

Fujita A, Ohkubo T, Hoshino H, Takabatake H, Tagaki S, Sekine K, Abe S - Br. J. Cancer (2003)

Bottom Line: The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and 30.7%, respectively.Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively.In conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of stage IIIB or IV NSCLC with acceptable toxicities.

View Article: PubMed Central - PubMed

Affiliation: Division of Respiratory Disease, Minami-ichijo Hospital, South-1 West-13, Chuo-ku, Sapporo 060-0061, Japan. afujita@sa2.so-net.ne.jp

ABSTRACT
A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF) support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Between June 1998 and August 2001, 50 patients were registered in this phase II study. Cisplatin (20 mg m(-2)) and ifosfamide (1.5 g m(-2)) were administered on days 1-4 and irinotecan (60 mg m(-2)) was given on days 1, 8, and 15, respectively. This regimen was repeated every 4 weeks. rhG-CSF was administered subcutaneously at a dose of 50 microg m(-2) on days 5-18 except on the days of irinotecan treatment. In total, 49 patients were assessable for toxicity and response and 50 for survival. In all, 33, patients (67.3%; 95% confidence interval 57.4-77.2%) achieved an objective response. The median response duration was 192 days and the median time to progression for 49 patients was 170 days. The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and 30.7%, respectively. Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively. In conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of stage IIIB or IV NSCLC with acceptable toxicities.

Show MeSH

Related in: MedlinePlus

Overall survival of 50 patients.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376953&req=5

fig1: Overall survival of 50 patients.

Mentions: All patients were assessed for survival, on the basis of intent to treat. With a median follow-up of 923 days, 17 patients were still alive. The median survival time was 540 days (95% CI, 522–558 days) with 1- and 2-year survival rates of 63.5 and 30.7%, respectively (Figure 1Figure 1


Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.

Fujita A, Ohkubo T, Hoshino H, Takabatake H, Tagaki S, Sekine K, Abe S - Br. J. Cancer (2003)

Overall survival of 50 patients.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376953&req=5

fig1: Overall survival of 50 patients.
Mentions: All patients were assessed for survival, on the basis of intent to treat. With a median follow-up of 923 days, 17 patients were still alive. The median survival time was 540 days (95% CI, 522–558 days) with 1- and 2-year survival rates of 63.5 and 30.7%, respectively (Figure 1Figure 1

Bottom Line: The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and 30.7%, respectively.Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively.In conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of stage IIIB or IV NSCLC with acceptable toxicities.

View Article: PubMed Central - PubMed

Affiliation: Division of Respiratory Disease, Minami-ichijo Hospital, South-1 West-13, Chuo-ku, Sapporo 060-0061, Japan. afujita@sa2.so-net.ne.jp

ABSTRACT
A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF) support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Between June 1998 and August 2001, 50 patients were registered in this phase II study. Cisplatin (20 mg m(-2)) and ifosfamide (1.5 g m(-2)) were administered on days 1-4 and irinotecan (60 mg m(-2)) was given on days 1, 8, and 15, respectively. This regimen was repeated every 4 weeks. rhG-CSF was administered subcutaneously at a dose of 50 microg m(-2) on days 5-18 except on the days of irinotecan treatment. In total, 49 patients were assessable for toxicity and response and 50 for survival. In all, 33, patients (67.3%; 95% confidence interval 57.4-77.2%) achieved an objective response. The median response duration was 192 days and the median time to progression for 49 patients was 170 days. The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and 30.7%, respectively. Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively. In conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of stage IIIB or IV NSCLC with acceptable toxicities.

Show MeSH
Related in: MedlinePlus